# Optimal Duration of Olanzapine Add-on Therapy in Major Depression

> **NCT00568672** · PHASE3 · WITHDRAWN · sponsor: **Charite University, Berlin, Germany**

## Conditions studied

- Relapse Rate of a Major Depressive Episode
- Safety of Olanzapine in Subjects With Major Depression

## Interventions

- **DRUG:** Olanzapine

## Key facts

- **NCT ID:** NCT00568672
- **Lead sponsor:** Charite University, Berlin, Germany
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2007-10
- **Primary completion:** 2008-01
- **Final completion:** 2008-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn because of personal ressources before inclusion of the first patient
- **Last updated:** 2023-02-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00568672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00568672, "Optimal Duration of Olanzapine Add-on Therapy in Major Depression". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT00568672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*